MDGL in the 13F filings
Madrigal Pharmaceuticals Inc · CUSIP 558868105
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 25
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 10 listed it in both
- Shares listed
- 5,341,480
- combined, among listed positions
- Reported value
- $2.8bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 13 buyers (opened or added shares) and 15 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,101,891.
Managers listing MDGL in Q1 2026
25 of 25 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 2,018,647 shares now+433,804
- Citadel Advisors LLCexisting position · 453,843 shares now+417,709
- Wellington Management Group LLPexisting position · 694,958 shares now+233,556
- AllianceBernstein LPexisting position · 125,447 shares now+103,535
- Point72 Asset Management LPexisting position · 225,510 shares now+99,075
Reductions
- D. E. Shaw & Co.existing position · 30,139 shares now-58,415
- Jane Street Group LLCexisting position · 35,838 shares now-57,276
- Susquehanna International Group LLPexisting position · 22,216 shares now-42,250
- Invesco Ltdexisting position · 329,519 shares now-35,795
- Squarepoint Ops LLCexisting position · 52,884 shares now-22,050
New positions and exits
New (1)
Exited (4)
- Steadfast Capital Management LPwas $16m
- Man Group PLCwas $8.6m
- Verition Fund Management LLCwas $5.2m
- Brevan Howard Capital Management LPwas $2.1m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2016 | 1 | $6.5m | n.a. | n.a. |
| Q1 2017 | 1 | $6.7m | n.a. | n.a. |
| Q4 2017 | 2 | $14m | n.a. | n.a. |
| Q1 2018 | 3 | $128m | n.a. | n.a. |
| Q2 2018 | 3 | $421m | n.a. | n.a. |
| Q3 2018 | 5 | $410m | n.a. | n.a. |
| Q4 2018 | 4 | $194m | n.a. | n.a. |
| Q1 2019 | 1 | $208m | n.a. | n.a. |
| Q2 2019 | 2 | $182m | n.a. | n.a. |
| Q3 2019 | 1 | $145m | n.a. | n.a. |
| Q4 2019 | 2 | $160m | n.a. | n.a. |
| Q1 2020 | 2 | $119m | n.a. | n.a. |
| Q2 2020 | 3 | $259m | n.a. | n.a. |
| Q3 2020 | 3 | $311m | n.a. | n.a. |
| Q4 2020 | 2 | $234m | n.a. | n.a. |
| Q1 2021 | 4 | $281m | n.a. | n.a. |
| Q2 2021 | 2 | $67m | n.a. | n.a. |
| Q3 2021 | 1 | $18m | n.a. | n.a. |
| Q4 2021 | 1 | $19m | n.a. | n.a. |
| Q1 2022 | 1 | $22m | n.a. | n.a. |
| Q2 2022 | 2 | $21m | n.a. | n.a. |
| Q3 2022 | 2 | $14m | n.a. | n.a. |
| Q4 2022 | 4 | $204m | n.a. | n.a. |
| Q1 2023 | 9 | $384m | n.a. | n.a. |
| Q2 2023 | 5 | $589m | n.a. | n.a. |
| Q3 2023 | 6 | $579m | n.a. | n.a. |
| Q4 2023 | 5 | $820m | 2 | 2 |
| Q1 2024 | 8 | $1.1bn | 6 | 1 |
| Q2 2024 | 7 | $1.1bn | 3 | 4 |
| Q3 2024 | 6 | $788m | 2 | 4 |
| Q4 2024 | 6 | $1.1bn | 2 | 3 |
| Q1 2025 | 7 | $1.2bn | 3 | 3 |
| Q2 2025 | 6 | $961m | 2 | 4 |
| Q3 2025 | 9 | $1.3bn | 6 | 2 |
| Q4 2025 | 12 | $1.8bn | 15 | 13 |
| Q1 2026 | 10 | $2.2bn | 13 | 15 |
| Q2 2026 | 11 | $2.3bn | 18 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MDGL and LLY →MDGL and JNJ →MDGL and VRTX →Choose a stock to compare with MDGL →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MDGL, latest filings →Back to the 13F Explorer →